Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0236
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SIM0236 (also known as MG-021) is a bispecific monoclonal antibody targeting both Programmed Death-Ligand 1 (PD-L1) and Roundabout Homolog 1 (ROBO1). Developed by Medgenn Bio (Shandong Simcere Medgenn), a subsidiary of Simcere Pharmaceutical, this therapeutic agent is designed to simultaneously block the PD-1/PD-L1 immunosuppressive checkpoint and inhibit ROBO1-mediated tumor signaling pathways. ROBO1 is a transmembrane receptor that, upon binding its ligand SLIT2, promotes tumor cell migration, invasion, and angiogenesis in various solid tumors. By dual-targeting these pathways, SIM0236 aims to restore anti-tumor immune activity while directly suppressing tumor progression and metastasis. The drug is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors.
- Other names
- SIM-0236SIM0236SIM 0236PD-L1/ROBO1 bispecific antibody
02
Targets
ROBO1 (Roundabout guidance receptor 1)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on SIM0236.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0236.